RxDoctor Payments Data

Anna Hohler, MD

Neurology · Brockton, MANPI 1689646606

Payments from drug & device makers

$126,458in general payments, 2019–2025

Across 116 payments — averaging $1090.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$120K
  • Boston Scientific$3K
  • Medtronic$2K
  • Acadia Pharmaceuticals Inc$439
  • Amneal Pharmaceuticals LLC$427
  • MDD US Operations, LLC$116
  • plus $283 from 4 others

What the payments were for

  • Travel & lodging$3,27351%
  • Food & beverage$3,09749%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,458 in reported general payments places this provider in the 80th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$157,575
Medicare patients
441
Services billed
1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate18$160,300
BetaseronInterferon Beta-1b13$124,754
RytaryCarbidopa/Levodopa41$86,225
Droxidopa19$62,074
GocovriAmantadine Hcl16$49,530
AustedoDeutetrabenazine11$48,626
Nurtec OdtRimegepant Sulfate22$38,679
Tetrabenazine13$33,005
Carbidopa-LevodopaCarbidopa/Levodopa681$29,656
Memantine Hcl473$23,873
Carbidopa-Levodopa ErCarbidopa/Levodopa191$22,999
Rasagiline Mesylate120$22,739
NeuproRotigotine14$21,059
Glatiramer Acetate15$20,776
AmantadineAmantadine Hcl290$19,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$439$160,30018 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$427$105,380161 claims
MDD US Operations, LLCGocovri$116$49,53016 claims
Teva Pharmaceuticals USA, Inc.Austedo$30$48,62611 claims
PfizerNurtec Odt$115$38,67922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 761 neurology providers in Massachusetts.

Other neurology in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →